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1. Ferrocenylisopropylamine (FIPA) inhibits the elimination of ampheta­
mines in rat. The half-life of isopropylamphetamine was increased from 
approx. 30 to 85—100 min after administration of FIPA.
2. With isolated, perfused, rat liver, the half-lives of isopropylamphetamine, 
biamphetamine and benzylamphetamine were increased from 5-20 min to about 
200 min by equimolar amounts of FIPA, indicating that the. prolonging effect 
of FIPA  is due to iriterference at the metabolic level.
3. Experiments with hepatic microsomal suspensions demonstrated that 
FIPA  competitively inhibits the oxidativé N-dealkylation of isopropylampheta­
mine ; the K i of FIPA  is 4-1 x 10_* M.
4. Binding of isopropylamphetamine and FIPA  to cytochrome P-450 was 
studied using hepatic microsomes of phenobarbital-treated rats. Isopropyl- 
amphétamine caused a type I, and FIPA  a type II  difference spectrum ; FIPA 
showed a much higher binding affinity (/Cs= 1-24 x 10 8 m) than isopropyl­
amphetamine (i£g =  0-96 x 10~3 m ). FIPA  acts as a modifiér of the spectral 
changes indüced by isopropylamphetamine.
5. Results suggest that the competitive inhibition of the N -dealkylation of 
Ar-aikylamphetamines, and thus the prolonging of their action, by FIPA  is 
related to competition for binding to cytochrome P-450.
Introduction
Amphetamines are metabolized to varying degrees, both in animals and man, 
via the following pathways : p-hydroxylation, deamination and iV-dealkylation. 
The contribution of each individual pathway to the total metabolism varies, 
dependent on species and on the particular amphetamine derivative. In man, 
for instance, amphetamines are slowly hydroxylated (Dring, Smith & Williams, 
1970), whereas in rats and guinea-pigs, this reaction occurs at a much faster rate. 
With a single species, differences in the degree of dealkylation and deamination 
occur dependent on the iV-alkyl substituent and the stereoisomer (Vree, Muskens 
& Van Rossum, 1971 a ; Vree et al., 1971 b ; Beckett, Brookes & Shenoy, 1969 ; 
Gunne, 1967). For example, scission of the C-H bond, in the a-C-oxidation 
mechanism, has been shown to be the rate-limiting step for dextroisomers only
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(Vree et al., 1971 a, b ; Parli, Wang & McMahon, 1971), whereas AT-oxide forma- 
tion may be a determinant step with the laevoisomers.
CHo-----CH----- NH2
I
c h 3
(I) (II)
Research in this laboratory is concerned with the metabolism of amphetamines 
(Vree, 1973), it therefore was of interest to extend these studies to ferrocenyliso- 
propylamine (FIPA) (I), a non-benzenoid aromatic analogue of amphetamine (II). 
FIPA has been reported to have little activity on the central nervous system 
(Loev & Flores, 1961). Current theory concerning pharmacological receptors 
postulates that agonist molecules must satisfy certain stereoelectronic prerequisites 
in order to interact effectively with a particular receptor (Ariëns, 1971). Ferro- 
cene, although aromatic is non-benzenoid and presents a considerable physico- 
chemical and stereochemical departure from benzene because of its cylindrical 
character. It might therefore be expected not to elicit a pharmacological response 
similar to that of amphetamine. Drug-metabolizing enzymes, on the other hand, 
have less structural specificity than pharmacological receptors, and are able to 
metabolize a variety of substrates. In these respects FIPA presented a unique 
compound for study. Although FIPA is an analogue of a potent pharmacologically- 
active agent, it is non-physiological as it contains an iron atom sandwiched between 
two cyclopentadiene rings, a structural arrangement which results in a considerable 
difference in bulk between FIPA and amphetamine.
In the present investigation, the influence of FIPA on the metabolism (N- 
dealkylation) of certain amphetamine derivatives was studied. Demonstration of 
competitive inhibition of the metabolism of amphetamine derivatives by FIPA 
would indicate that this compound had an affinity for the enzyme system concerned 
and might present substantial sterical hindrance to the approach of other substrates. 
The effects of ( + )FIPA on the metabolism of (+  )isopropylamphetamine and 
(+  + )biamphetamine were therefore studied. These compounds were chosen 
because of their short metabolic half-lives (isopropylamphetamine, 20 m in ; 
biamphetamine, 10 min) compared to amphetamine (200 min) (Vree et al., 
1971 b), as within the limits of experimental procedure, it is easier to demonstrate 
inhibition of metabolism (increase in t0.s) with compounds that normally have a 
short half-life.
Studies were carried out in vivo in rats, and in vitro with isolated perfused rat 
liver and hepatic microsomal suspensions. Cytochrome P-450, the terminal 
oxidase in the oxidative transformation of drugs, is generally believed to be the 
site for substrate interaction (Schenkman, 1970). Studies concerning the binding 
to this enzyme system, were, therefore, included.
Materials and methods
Animals
Adult male rats weighing 200-260 g were used. Phenobarbital-treated animals 
received 75 mg/kg sodium phenobarbital in saline intraperitoneally daily for 5 days.
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In the in vivo experiments rats were injected intravenously with soln. of (+  )iso- 
propylamphetamine HCI and ( ± )ferrocenylisopropylamine HBr in saline. Blood 
samples (0-5 ml) were taken at regular intervals from the orbital plexus.
Isolated perfused rat liver experiments
Livers (9-14 g) were surgically removed from rats and perfused with Schimassek 
(1962) soln. as modified by Alvarez (1971). The liver and oxygenated (95% 0 2, 
5% C 0 2) perfusate were maintained in a humidified chamber at 37°. Prepara- 
tion of perfusion fluid was as follows: 100 ml human blood was centrifuged, 
the plasma removed by suction, and the remaining cells washed three times with 
Schimassek soln. The washed erythrocytes (10 ml) were mixed with 3 g bovine 
albumin, 0-150 g glucose and enough Schimassek soln. to make 100 ml. This 
prep. of artificial blood was carried out under aseptic cónditions. One litre of 
Schimassek soln. contained the following salts : NaCI 137 mM ; KC1 2-68 mM ; 
CaCl21-80 mM ; MgCl2 0-49 mM ; NaHCOg 11-9 mM ; NaHgP04 . HaO 0-67 mM ; 
it was sterilized by filtration.
The isolated liver was perfused with 100 ml perfusion fluid at a rate of 12 ml/ 
min (Cardiac Suction Unit pump, type 913, New Electronic Products Ltd, 
London). The perfused isolated liver prep. was allowed to equilibrate for 1 h 
prior to an experiment. Liver function was monitored by the vol. of bile produc- 
tion. Test compounds were dissolved in perfusion fluid, and, at regular time 
intervals, 0-5 ml samples perfusion fluid were treated as indicated in the g.l.c. 
analysis.
Preparaiion of microsomes
Rats starved overnight, to remove liver glycogen, were killed by decapitation 
under Jight ether anaesthesia. The livers were rapidly excised, portions were 
weighed, finely minced and transferred into 9 vol. ice-cold 0-25 M-sucrose. 
Homogenates were made using a Teflon-glass Potter-Elvehjem type homogenizer. 
After sedimentation of nuclei and cell debris by centrifugation at 500 g, the 
supernatant was centrifuged at 18 000 g for 10 min ; the microsomal fraction was 
isolated by centrifugation of the 18 000 g supernatant at 105 000 g for 60 min. 
The microsomal pellet was washed once to remove contaminating haemoglobin 
and carefully re-suspended in isotonic KC1 soln. (0*15 m ), containing 0-05 M-Tris- 
HC1 (pH 7-5).
Determination of microsomal dealkylation
The microsomal suspension was used as the enzyme source for the measure- 
ment of iV-dealkylation of (+  )isopropylamphetamine in vitro. Incubations were 
carried out at 37°, under air, as described earlier (Henderson & Kersten, 1970). 
Incubation media contained : 5 x 10~2 m Tris-HCl (pH 7-5); 8 x 10~4 M-MgCl2 ; 
8 x 10_a M-MnCl2; 5 x 10-8 M-sodium isocitrate ; isocitric dehydrogenase 20 /ig/ 
ml (Sigma type IV ; capable of generating 5-5 /xmol NADPH/min/mg at 37°); 
13 x 10~5 m-NADP ; and (+  )isopropylamphetamine as indicated. The mixture 
was preincubated at 37° for 10 min, to ensure reduction of all NADP. The 
reaction Was started by addition of the microsomal suspension, equivalent to 4 mg 
protein per ml. After incubation for 30 min, the reaction medium was made 
alkaline with KOH and extracted with ether. The amount of amphetamine
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formed was determined by g.l.c. Blanks containing all reaction components 
including heat-denatured enzyme were similarly treated to detect non-enzymic 
formation of metabolites.
Microsomal difference spectra
For the measurement of difference-spectra the above microsomal suspension 
was diluted with 0-15 m-KCI-0-05 M-Tris-HCl (pH 7-5) to a concn. of about 1 mg 
microsomal protein per ml and was divided between two cuvettes. The substrate 
dissolved in 0*15 M-KCl-Tris-HCl (pH 7-5) was added to the sample cuvette, and 
ari equal vol. of buffer was added to the reference cuvette. At varying substrate 
concn., difference-spectra were recorded with a Beekman DB-G spectrophoto- 
meter. When FIPA was used as a modifier of the spectral changes (Leibman, 
Hildebrandt & Estabrook, 1969) induced by ( 4- )isopropylamphetamine, it was 
added to the microsomal suspension in both cuvettes.
All spectra were measured at room temp. in the absence of NADPH. Micro­
somal protein concn. were determined by the method of Lowry, et al. (1951).
Gas chromatographic analysis
An internal Standard, methylbenzylamine (10 f i g )  was added to 0-5 ml samples 
of perfusion fluid, and the resulting soln. made alkaline with 2 ml 20% KOH, 
extracted with 10 ml freshly distilled ether, and the ether extract conc. to 100 fx\ 
in a stream of dry air. The conc. extract (5 ,^1) was injected into the g.l.c. and the 
concn. of the test compounds and their metabolites calc. relative to the internal 
Standard. The g.l.c. instrument was a Hewlett Packard Model 402, with flame 
ionization detector, and a Mosely recorder model 7127 (1 mV full scale deflec- 
tion). The operating conditions were as follows : 20% Apiezon 5% KOH on 
Gaschrom Q60-80 mesh, or 3% Carbowax 2% KOH on Gaschrom Q60-80 
mesh, in a column 1-80 m by 3-0 mm diam. ; carrier gas flow rate : N 2, 20 ml 
per min ; H 2, 30 ml per min ; air, 150 ml per min ; temp. : oven 160° ; flash 
heater 200° ; detector 200°.
Synthesis
All compounds were prepared according to previously published methods 
(Loev and Flores, 1961 ; Vree, et al., 1971 b) and their purity established by 
m.p., i.r., u.v., n.m.r. and mass spectral data.
Results
A. In vivo metabolism in rats
The results of these experiments are presented in Table 1. Rats rapidly 
eliminate isopropylamphetamine and the half-life for this compound is approx. 
30 min. FIPA had a half-life of approx. 200 min (120-300 min), which is similar 
to that of amphetamine itself. Administration of (±  )FIPA, in suitable concn., 
together with (+  )isopropylamphetamine caused a change in the half-life of the 
latter to 85-100 min (Table 1, Fig. 1). In order for this effect to become manifest, 
the blood concn. of FIPA had to be of the same order as isopropylamphetamine. 
This was due to the large difference in the fictive volume of distribution
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T  able  1.
by th e  ra t
T he fictive volume, Vt =  D /C0 =  dose/blood concn. at t= 0  
F t ferrocenylisopropylamine
Vt ( +  )isopropylamphetamine = 5-8.
Rat Compound
Dose 
(/i mol) *0-5 .(min)
V t(ml)
A ( +  ) I sopropylamphetamine 5-95 25 503
A ( +  ) Isopropylamphetamine 1-48 30 580
B ( +  ) Isopropylamphetamine 4-25 30 576
A ( ± )Ferrocenylisopropylamine 39-2 180 4080
A ( + )Ferrocenylisopropylathine 13-9 120 2880
B ( ± )Ferrocenylisopropylaihine 3-87 300 2770
A ( +  ) Isopropylamphetamine 3-96 85 775
plus
ferrocenylisopropylaminé 13-9 130
B ( +  ) Isopropylamphetamine 4-25 100 576
plus
ferrocenylisopropylamine 14-9 120
zol-<rcci-
zUiozoo
ooo_Jco
0  20 40  60 80 100 
TIME AFTER D0SAGE (min) 
( a )
-60 O 20 40  60 80 100 120 140 
TIME AFTER D0SAGÉ (min)
(b)
Fig. 1 Blood concentration of (+  )isopropylamphetamine and (+  )ferrocenylisopropylamine 
af ter intravenous dosage to rats.
Rat A was injected intravenously with (+  )isopropylamphetamine and ( ± )ferro- 
cenylisopropylamine (FIPA) and blood concn. of the compounds were estimated at 
different time intervals.
In  the experiment shown in (a), (+  )isopropylamphetamine (0-79 mg) and 
( ±  ferrocenylisopropylamine (0-78 mg) were injected but the amount of FIPA  
was top low for inhibition. The t0.5 óf (+  )isopropylamphetamine (25 min) was 
the same as observed incöntrol experiments ; A. =  isopropylamphetamine ; O =  ferro­
cenylisopropylamine. In  (b) inhibition of elimination of ( +  )isopropylamphetamine 
(0-7 g) is shown after intravenous administration of a suitable dose of FIPA  (3-61 mg), 
injected 1 h before isopropylamphetamine in order to avoid interference by the 
distribution phenomenon as shown in ( a ) ; ^  =  isopropylamphetamine 
(t#-6 =  85 min) ; O = ferrocenylisopropylamine (t0.6 =  130 min).
(Vt = dose/blood concn. at zero, time) between the two compounds, for, as can 
be seen from the data in Table 1, FIPA has a V{ approx. 6 times greater than 
isopropylamphetamine. The prolongation of the half-life of isopropylampheta- 
mine by FIPA indicates that the latter compound hinders the elimination of the 
former in vivo.
B. Isolated perfused liver experiments
The results of these experiments are presented in Tables 2 and 3. The half- 
life times of metabolism and the fictive volumes of distribution of a number of 
amphetamine derivatives are given in Table 2. Amphetamine and its JV-methyl 
and JV-ethyl derivatives have metabolic t0.B values of between 100 and 200 min. 
In contrast to this, the higher homologues, (+  )isopropylamphetamine, (+  )benzyl- 
amphetamine and (+  + )biamphetamine, have metabolic t0.5 values of between 5 
to 20 min. The TV-alkyl amphetamines as a group are dealkylated in the isolated 
liver prep. to amphetamine as shown schematically below :
Table 2. Half-life tim es of m etabolism  and fictive volum es of distribution of 
som e am phetam ines in the isolated perfused rat liver
Vt ferrocenylisopropylamine _  
Vt ( +  )isopröpylamphetamine
Exp. Compound
Dose 
(/i mol/liver) tob(min)
Vt
(ml)
Liver 
wt. (g)
4 (+  ) Isopropylamphetamine 29-6 20 129 12-4
21 ( + )  Isopropylamphetamine 40-6 20 115 14-4
28 (4-) Isopropylamphetamine 27-6 20 192 11-7
13 ( — ) Isopropylamphetamine 360 43 129 14-4
14 ( +  )Benzylamphetamine 24-8 13 187 10-9
15 ( — )Benzylamphetamine 240 20 175 13-3
23 (+  +  )Biamphetamine 200 20 167 9-4
29 ( +  +  )Biamphetamine 18-5 5 190 9-7
30 (+  +  )Biamphetamine 190 5 120 10-5
31 (+  + )Biamphetamine 28'2 5 125 9-3
17 ( H—  )Biamphetamine 20-6 27 185 9-9
19 F  errocenylisopropy lamine 18-6 400 900 10-6
20 Ferrocenylisopropylamine 260 200 700 7-7
21 Ferrocenylisopropylamine 28-6 120 775 14-4
23 Ferrocenylisopropylamine 280 200 600 9-4
31 Ferrocenylisopropylamine 24-8 130 300 9-4
28 N -isopropyl ferrocenylisopropylamine 25-8 50 500 11-7
30 iV-isopropyl ferrocenylisopropylamine 16-6 40 1000 10-5
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Table 3. Inhibition o f m etabolism  of (+  )isopr«pylam phetam ine and (+  +)fci- 
am phetam ine by ferrocenylisopropylam ine in  isolated perfused rat liver
Dose <0 4 Vt Liver
Exp. Compound (n mol/liver) (min) (ml) wt. (g)
20 ( +  ) Isopropylamphetamine 
plus
24-7 240 145 7-7
ferrocenylisopropylamine 260 200 700
21 (+  ) Isopropylamphetamine 
plus
40-6 200 14-4
ferrocenylisopropylamine 28-6 120 775
28 ( +  ) Isopropylamphetamine 
plus
27-6 200 192 11-7
Af-isopropyl ferrocenylisopropylamine 25-8 50 500
23 ( + +  )Biamphetamine 
plus
200 160
ferrocenylisopropylamine 280 200 600 9-4
Isopropylomphetomine 
\  *0-5 ~  20 min
t0.5 * 8 0  min
t. i I i 1
I sopropy lomptietamine 
* 0 - 5  “  * 5  m i n
20 60 100 140 180 220 260 300 
TIME AFTER D0SAGE (min)
(0 )
TIME AFTER DOSAGE (min) 
(b)
Fig. 2. Metabolism of ( -isopropylamphetamine in the isolated perfused rat liver.
(a) Metabolic conversion of (+  )isopropylamphetamine into amphetamine. (+  )N- 
isopropylamphetamine HC1 (7-2 mg) was added to the perfusion system. (b) 
Inhibition of metabolism. of isopropylamphetamine and amphetamine. (+  )N~iso- 
propylamphetamine HC1 (5-25 mg) and ( ± )ferrocenylisopropylamine H B r (6-20 mg) 
and ( ± )ferrocenylisopropylamine HBr (6-20 mg) were added to the perfusion 
system. In  order to elicit a clear-cut inhibition, ferrocenylisopropylamine was 
added about 40 min after the ( +  )isopropylamphetamine.
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FIPA was hardly metabolized during the period of the experiment and therefore 
has a long metabolic t0.s, oi the order of 300 min. When FIPA and isopropyl­
amphetamine were added in equimolar amounts to the perfused liver system the 
metabolic t0.5 of the Iatter was changed from 20 min to approx. 200 min (Fig. 2, 
Tables 2 and 3) indicating a considerable inhibition of metabolism. The result 
of this inhibition was a fairly constant concn. of amphetamine (by dealkylation of 
isopropylamphetamine) over a long period of time. Similar results were obtained 
when FIPA was combined with benzylamphetamine and biamphetamine.
When iV-isopropyl FIPA was added to the perfused liver prep., FIPA was 
detected as the metabolite, which suggests that FIPA is reversibly boünd to the 
metabolizing enzyme system.
C. Effect of ferrocenylisopropylamine on the microsomal N-dealkylation of (+)iso- 
propylamphetamine
The influence of (±  )FIPA on the oxidative Af-dealkylation of (+  )isopropyl- 
amphetamine was investigated by incubating the compounds in suspensions of 
rat liver microsomes. The rates of enzymic conversion of (+  )isopropylampheta- 
mine were measured at constant substrate concn. with varying concn. of inhibitor.
-4 0 80 100-2 0  0  20 40 60
FERROCENYLISOPROPYLAMINE ( I0 -6  m)
Fig. 3. Dixoti plot of the effect of ferrocenylisopropylamine on the N -dealkylation of ( + )iso- 
propylamphetamine by hepatic microsomes.
Abscissa : concn. of ferrocenylisopropylamine ; ordinate : reciprocal rate of enzymic 
conversion, expressed as /xmol amphetamine formed/h/mg microsomal protein. 
Conditions are as described in Methods ; livers of phenobarbital-treated rats were 
used.
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Data were treated according to Dixon (1953) and the results are shown in Fig. 3. 
The results indicate a competitive inhibition of microsomal dealkylation by 
( ± )FIPA. The inhibitor constant (K^) was calculated to be 4-1 x  10~6 M.
D. Interactions at the level of cytochrome P-^50
Addition of (+  )isopropylamphetamine and (+ )F IPA  to microsomal suspen­
sions derived from rat liver produced characteristic spectral changes. Two 
distinct types of difference spectra were observed with these compounds. (+  )Iso- 
propylamphetamine caused a type I spectrum, which is shown in Fig. 4 ;  the 
absorbance changes at the max. (395 nm) and at the trough (425 nm) appeared 
to be related to the concn. of substrate. Double reciprocal plots of these data 
were made: according. to the. method of Lineweaver. and Burk, and an apparent 
dissociation constant (Ks) of O-96 ± 0-18 x 10-3 M was obtainèd ifor (+  )isopropyl- 
amphetamine. This value corresponds very well with the apparent K m of 
0-67 x 1 0-3 M' determined during the microsomal dealkylation experiments. 
(+:)FIPA, on the other hand, gave a type I I  difference spectrum with a peak and 
a trough at 425'and 395 nm, respectively (see Fig. 5 ); an apparent K s of 1-24 
+ 0-15?x 10 '6 m  was calculated from a Lineweaver Burk plot (Fig. 6). The value 
of this spectral dissociation constant is of the same order of magnitude as the K i 
measured: för ( ± )EIPA (4-l x  10_6 m) determined during the inhibition of micro­
somal dealkylation of ( +  )isopropylamphetamine.
Fig. 4. Type I  spectral changes obtainèd on addition of ( +  )isopropylamphetamine, at different 
concentrations, to hepatic microsomes of rats pretreated with phenobarbital.
The microsomes were: diluted. whh. Tris-KCl (pH 7-5) to a*final concn. of 1 mg 
protein (+  isopropylamphetamine was added at the following concn. : ml (a) 
5 x  10~4 m  ; (6) l x 10"-® m  ; (c) 2 x 10~3 m  ; and (d) 5 x 10~3 M .
Preliminary studies revealed that FIPA is deaminated, although slowly, to 
ferroceaiylacetone by microsomal preparations from rat liver in the presence of 
NADPH. This may indicate. that FIFA itself: can also serve as a substrate for 
microsomal oxidation and.probably binds to cytochrome P-450 at the active site. 
As mentioned previously, iV-isopropyl-FIPA is dealkylated to FIPA. Since
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deamination and iV-dealkylation are considered to be the result of one enzymic 
action, a-C-oxidation (Becket, 1971 ; Vree, et al., 1971 a), the relatively fast 
dealkylation of AT-isopropyl-FIPA and the simultaneous inhibition of isopropyl- 
amphetamine (Table 3) also support the idea that these ferrocenes bind at the 
active site of P-450. Since the K H can be regarded as an inverse measure of the 
affinity of a particular substrate for cytochrome P^450, the large difference in the 
spectral dissociation constants of (+  )isopropylamphetamine and (± )F IP A  
substantiates the view that the latter compound would act as a competitive in- 
hibitor.
WAVELENGTH (nm)
Fig. 5. Type I I  spectral changes observed after addition of different concentrations of 
ferrocenylisopropylamine to liver microsomes of rats pretreated with phenobarbital.
The final microsomal protein concn. was 1 m g/m l; ferrocenylisopropylamine was 
added at the following concn.: (a) 5 x 10~7 M ; (b) 1 x 10~6 m ; (c) 3 x 10® M ; 
and (d) 5 x 10-6 M.
[ f e r r o c e n y l is o p r o p y l a m in e ] -1 ( I0 '6M)
Fig. 6. Lineweaver-Burk plot of the spectral changes induced by addition of 
ferrocenylisopropylamine to rat liver microsomes.
The microsomal suspension contained 1 mg of protein/ml. The changes in 
absorbance were calc. at 395 and 425 nm, with respect to the base line.
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The effect of ( + )FIPA upon the binding of (+  )isppropylamphetamine to 
cytochrome P-450 was also studied. In these experiments, difference spectra 
were recorded after the addition of increasing amounts of (+  )isopropylampheta- 
mine, in the presence of a constant concn. of ( ± )FIPA (the inhibitor was added 
to the microsomal suspensions beforehand). A double reciprocal plot was made 
öf the sum of the absorbance changes at the peak and the trough against thé concn. 
óf (+  )isopropylamphetamine (Fig. 7). It may be seen that the (±  )FIPA acts 
as a competitive inhibitor; the K s of (+  )isopropylamphetamine was changed 
from 0*83 x 10~3 M in the control experiment, to 1-45 and 4-15x10-3 m in the 
presence of 1*0 and S-OxlO^M  (±)FIPA , respectively. Analogously to the 
classïcal competitive inhibition model in enzymology, a dissociation constant of 
( ± )FIPA (spectral K j) can be calculated and amounts tó 1-30 x 10-8 M on average. 
This value is quite similar to the üC8-value of (+  )FIPA (1-24 x 10-8 m).
Diseussion
The data presented herein clearly demonstrate that FIPA competes for sites 
on the enzymes that normally metabolize amphetamine derivatives. This further 
indicates that the enzymes are capable of accommodating very bulky substrates ; 
in fact, in the present study, FIPA demonstrated a 1000-fold greater affinity to the 
enzyme system, when compared with (+  )isopropylamphetarnine. It would be 
reasonable to assume at this point that the ferrocenyl moiety contributes sub- 
stantially to this increase in binding energy.
FIPA was also a competitive inhibitor for the Ar-demethylation of aminopyrine 
(a-C-oxidation), and it remains to be determined whether or not FIPA is a general 
inhibitor of microsomal oxidations.
In the in vivo situation, the relative Vt values of FIPA and isopropylampheta= 
mine determine the effectiveness, via distribution, of the former compound as a
0 x
-10 - 5  O 0-5 10 15
[]+) is o p r o p y l a m p h e t a m in e ] -1 ( I0 “ 3 m )
Fig. 7. Effect of ferrocenylisopropylamine upon the spectral changes induced by addition of 
(+  ^isopropylamphetamine to rat liver microsomes (Lineweaver-Burk plot).
Livers of phenobarbital-treated rats were used. The microsomal suspension con- 
tained 1 mg of protein/ml. Apparent K’s-valués of (+  )isopropylamphetamine are 
shifted tó higher concn. by the presence of ferrocenylisopropylamine.
XB. C
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competitive inhibitor of liver iV-dealkylation. The Vt ratio of FIPA/isopropyl- 
amphetamine is approximately 6, indicating that the ferrocenyl derivative is much 
more widely distributed throughout the body tissues. This corresponds very well 
with the work of Dratz, Coberly & Goldstein (1964), in which it was shown that 
radioactively labelled ferrocene initially concentrates in fat tissue in large quanti- 
ties. However, as partition experiments in our laboratory indicate that iso­
propylamphetamine is at least 10 times more lipid-soluble than FIPA (see Table 4), 
the difference in the Vt values might be explained by selective binding.
Table 4. Apparent and true partition coefficients of am phetam ine, 
ferrocenylisopropylam ine, and derivatives
Compound pKa APCh* APCchl* TPChf TPCcmt
Amphetamine 9-90 0-005 0-48 1-88 146
Isopropylamphetamine 1014 0-21 8-09 117 4460
F erroceny lisopropylamine 970 0-075 2-33 15-0 466
jV-Isopropylferrocenyl-isopropylamine 9-85 4-00 99-0 1130 28 000
*APC = apparent partition coëfficiënt. 
fT C P  = true partition coëfficiënt;
h =  w-heptane-water (Theorell buffer, pH  7-4) ; 
chl =  chloroform-water (Theorell buffer, pH  74).
Increase of the FIPA/isopropylamphetamine molar ratio, as in our in vivo 
experiments, results in a proportionate increase in the initial FIPA concentration 
obtained in the liver, which permits the compound to exert a measurable inhibition 
of metabolism. Dratz, et al. (1964) have also shown that after rapidly attaining 
high concentrations in fat tissue, ferrocene then attains (1 or 2 days after oral 
administration) concentrations in the liver which are higher than those in the fat.
Use of isolated perfused liver preparations obviates the problems inherent in 
the in vivo situation (viz. : the relative distribution patterns of the compounds 
being examined) and permits study on a more controlled level. Indeed, as can 
be seen from the in vitro data, once the effects of distribution are removed, FIPA 
exerts its competitive inhibition at concentrations considerably lower than those of 
the substrate isopropylamphetamine.
The results in vivo and in vitro substantiate each other, and indicate that, 
although FIPA has considerable differences in structure from the arylalkylamines 
that are normally metabolized by the hepatic microsomal enzymes, it nevertheless 
demonstrates a considerable affinity for these enzymes. This is another example 
of the less rigid structural specificity of drug-metabolizing enzymes, when com- 
pared with pharmacological receptors.
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